The 2025 IV pilot measured cardiac, hepatic, renal, thyroid, and glucose biomarkers and reported no abnormalities (Lee et al., 2025), which gives a sense of what those investigators considered worth checking
The updated protocols introduce expanded inspection procedures at multiple checkpoints, beginning with supplier evaluation and continuing through warehousing, packaging, and dispatch
Lets look at what we currently know
Where it's most often discussed: Tissue repair and recovery models (especially tendons/ligaments and muscle) Wound healing and regenerative signaling Gut integrity and inflammation-related pathways Where it's not firmly established: Extensive, rigorous human studies designed to measure fat loss outcomes (fat mass, waist circumference, body fat percentage) That distinction matters